公开(公告)号：US20230242649A1

公开(公告)日：2023-08-03

申请号：US17777021

申请日：2020-11-16

Applicant: ENTHERA S.R.L.

Inventor： Paolo FIORINA ,  Giovanni AMABILE ,  Francesca D'ADDIO

IPC: C07K16/28 ,  A61P3/10 ,  C12N15/63

CPC classification number: C07K16/2863 ,  A61P3/10 ,  C12N15/63 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2317/24

Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind specifically to the IGFBP3 receptor, namely TMEM219, to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US20230192827A1

公开(公告)日：2023-06-22

申请号：US17800407

申请日：2021-02-19

Applicant: ENTHERA S.R.L.

Inventor： Giovanni AMABILE

IPC: C07K16/18 ,  A61P11/00 ,  A61P19/04

CPC classification number: C07K16/18 ,  A61P11/00 ,  A61P19/04 ,  C07K2317/21 ,  C07K2317/24

Abstract: The present invention relates to inhibitors of IGFBP5 and/or of at least one of its receptors, wherein said inhibitor has anti-fibrotic effect, methods for their production, pharmaceutical compositions containing said inhibitors, and uses thereof. In particular, the invention relates to antibodies or antigen binding fragments thereof that bind specifically to human IGFBP5 and/or to at least one of its receptors.

公开(公告)号：US20240368290A1

公开(公告)日：2024-11-07

申请号：US18772062

申请日：2024-07-12

Applicant: ENTHERA S.R.L.

Inventor： Paolo FIORINA ,  Giovanni AMABILE ,  Francesca D'ADDIO

IPC: C07K16/28 ,  A61P3/10 ,  C12N15/63

Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind specifically to the IGFBP3 receptor, namely TMEM219, to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US20230039165A1

公开(公告)日：2023-02-09

申请号：US17778814

申请日：2020-11-20

Applicant: ENTHERA S.R.L.

Inventor： Giovanni AMABILE ,  Paolo FIORINA ,  Francesca D'ADDIO

IPC: C07K16/22 ,  C12N15/66 ,  A61P7/00

Abstract: The present invention relates to antibodies or antigen binding fragment thereof that binds specifically to IGFBP3. The antibody inhibits or reduces the binding of IGFBP3 to the TMEM219 receptor. The invention also relates to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.